Onconetix to Acquire Realbotix in All-Stock Deal

• Onconetix agreed to acquire Realbotix LLC in an all-stock transaction announced February 12, 2026.
• Onconetix advanced an initial $2,500,000 bridge financing facility to Realbotix LLC.
• The closing cash requirement will be reduced by the total principal advanced plus an additional $500,000.
• The combined company is expected to list on Nasdaq.

Deal Terms

Onconetix agreed on February 12, 2026 to acquire Realbotix LLC, a subsidiary of Realbotix Corp., in an all-stock transaction.

The deal remains subject to shareholder approval, regulatory approvals, and other closing conditions.

Bridge Financing

Onconetix provided a bridge financing facility to Realbotix LLC, with an initial advance of $2,500,000.

The facility is non-interest bearing prior to closing.

At closing, the facility will be automatically cancelled and discharged in full.

The closing cash requirement will be reduced by the total principal advanced plus an additional $500,000.

Business Profiles

Onconetix is a commercial-stage biotechnology company focused on oncology solutions.

It holds a license agreement with Labcorp and owns Proclarix®, which is approved for sale in the European Union under the IVDR.

Realbotix LLC develops AI-powered humanoid robots for enterprise and consumer environments, manufactured in the United States.

Path to Closing

Onconetix intends to file a Registration Statement on Form S-4 for the transaction.

The combined company is expected to list on Nasdaq.

Onconetix filed its 10-K on March 13, 2026.